<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The authors present 5-year survival of 64 patients with <z:hpo ids='HP_0001915'>aplastic anemia</z:hpo> (AA) divided into 2 groups </plain></SENT>
<SENT sid="1" pm="."><plain>Group 1 received antilymphocytic globulin (ALG) in low doses (1-5 mg/kg), group 2 in high doses (10-30 mg/kg) </plain></SENT>
<SENT sid="2" pm="."><plain>Survival of patients with severe AA in group 1 made up 28.5%, with mild AA 90.1% </plain></SENT>
<SENT sid="3" pm="."><plain>Overall survival in group 1 was 64.4%, in group 2 53.8% </plain></SENT>
<SENT sid="4" pm="."><plain>Overall toxicity came to 48.6% </plain></SENT>
<SENT sid="5" pm="."><plain>By resultant complications high and low ALG doses did not differ </plain></SENT>
<SENT sid="6" pm="."><plain>The authors propose to use low doses of ALG in mild disease whereas in severe condition high ALG doses are thought adequate </plain></SENT>
</text></document>